drugset / Trial / NCT05012618
A Dose-escalation Study of LUNA18 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a Phase 1 dose-escalation and cohort expansion study that will evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary activity of LUNA18 when administered as a single agent or in combination with other anti-cancer drugs in patients with locally advanced or metastatic solid tumors.
Timeline
- Start
- 2021-10-08
- Primary completion
- 2025-11-13
- Completion
- 2025-11-13
Outcome
Outcome not reported
Stopped: “Sponsor decided to discontinue this study upon having LPLV.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cetuximab | Monoclonal antibody | — | Intravenous |
| Subject | LUNA18 | Unknown | — | — |
Indications
No indication recorded.